Acute Coronary Syndrome, Atherosclerosis, Cardiovascular Disease, Dyslipidemia
Conditions
Keywords
Cholesterol, High density lipoprotein, Dyslipidemia, Atherosclerosis, Apolipoprotein A-I
Brief summary
The purpose of this study is to investigate an oral formulation of RVX000222 for safety, pharmacokinetic and efficacy in healthy subjects.
Detailed description
One-third of the US population, almost 80 million adults, have cardiovascular disease and mortality associated with heart disease which still remains a leading cause of death around the world. The major risk factors for cardiovascular disease associated with atherosclerosis is dyslipidemia, characterized by high levels of low density lipoprotein (LDL) and/or low levels of high density lipoprotein (HDL). HDL has a well established role in atherosclerosis and cardiovascular disease protection. HDL mediates the removal of cholesterol from the atherosclerotic plaques for elimination from the body. The major component of HDL consists of apolipoprotein A-I (ApoA I). Recent intervention studies with synthetic HDL particles and recombinant ApoA-I have shown that HDL has the capacity to reverse coronary atherosclerosis. RVX000222 is a member of a novel class of small molecules that are candidates for the treatment of dyslipidemia by increasing plasma levels of ApoA-I and HDL.
Interventions
DRUGRVX000222
RVX000222 twice daily (b.i.d.) for 28 days
DRUGPlacebo
Placebo twice daily (b.i.d.) for 28 days
Sponsors
Resverlogix Corp
Study design
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
DOUBLE (Subject, Investigator)
Eligibility
Sex/Gender
ALL
Age
18 Years to 65 Years
Healthy volunteers
Yes
Inclusion criteria
* Subjects who meet the following criteria may be enrolled: 1. Be men or women between 18 and 65 years old, inclusive 2. Weigh between 60 kg and 110 kg, inclusive, and have a BMI ≥25 kg/m2. 3. Healthy volunteers with normal or low HDL 4. If female, non-pregnant (as determined by a negative serum pregnancy test at Screening), non-lactating, and not of childbearing-potential or willing to practice an acceptable form of birth control. If male, be willing to practice an acceptable form of birth control.
Exclusion criteria
* Subjects who meet any of the following criteria will not be enrolled: 1. Have presently, or have a history of, clinically significant disease, including cardiovascular, gastrointestinal, renal, hepatic, pulmonary, endocrine, hematologic, vascular, immunologic, metabolic, neurological, or collagen disease, as judged by the Investigator. 2. Have active cholecystitis or gallbladder symptoms within 60 days prior to Check-in (subjects who have had a cholecystectomy are not excluded from this study). 3. Have had a clinically significant illness, in the opinion of the Investigator, within 30 days prior to Check-in. 4. Have hypertension that is currently being treated, or uncontrolled hypertension 5. Have a serum creatinine \>1.5 mg/dL, hemoglobin \<11.2 g/dL, or white blood cell count \<4000/μL. 6. Have positive test results for HIV, hepatitis A, B, or C. 7. Have a positive result on drug screen testing.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Safety, pharmacokinetics and changes in lipid parameters from baseline and placebo. | 1-month |
Countries
United States
Outcome results
None listed